Ascendis Pharma A/S
ASND
$207.71
$7.213.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 103.22% | 55.68% | 10.59% | 35.98% | 117.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 103.22% | 55.68% | 10.59% | 35.98% | 117.21% |
| Cost of Revenue | 76.90% | 64.27% | 13.18% | -0.41% | 66.65% |
| Gross Profit | 107.92% | 54.24% | 10.16% | 43.26% | 129.68% |
| SG&A Expenses | 49.77% | 34.44% | 21.41% | 10.07% | 8.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.82% | 11.63% | 0.59% | -11.10% | -9.16% |
| Operating Income | 54.31% | 27.92% | 8.49% | 38.61% | 43.31% |
| Income Before Tax | 45.80% | 45.02% | 32.06% | 21.15% | 28.50% |
| Income Tax Expenses | 5.28% | -21.63% | -60.39% | -33.24% | 45.59% |
| Earnings from Continuing Operations | 44.66% | 44.59% | 32.53% | 21.33% | 27.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.66% | 44.59% | 32.53% | 21.33% | 27.68% |
| EBIT | 54.31% | 27.92% | 8.49% | 38.61% | 43.31% |
| EBITDA | 56.86% | 28.98% | 8.55% | 39.73% | 44.46% |
| EPS Basic | 47.57% | 46.82% | 34.74% | 22.97% | 28.91% |
| Normalized Basic EPS | 48.64% | 47.22% | 34.27% | 22.80% | 29.72% |
| EPS Diluted | 47.57% | 46.82% | 34.74% | 22.97% | 28.91% |
| Normalized Diluted EPS | 48.33% | 46.93% | 35.50% | 24.07% | 30.76% |
| Average Basic Shares Outstanding | 5.56% | 4.73% | 3.87% | 2.85% | 1.69% |
| Average Diluted Shares Outstanding | 5.47% | 4.66% | 5.40% | 4.38% | 3.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |